References
- Ashida S., Abiko Y. Inhibition of platelet aggregation by a new agent ticlopidine. Thrombosis and Haemostasis 1979; 40: 542–550
- Bruno J. J., Molony B. A. Ticlopidine. New Drugs Annual: Cardiovascular Drugs, A. Scriabine. Raven Press, New York 1983; 295–316
- Colli A., Buccino G., Cocciolo M., Parravicini R., Elli G. M., Scaltrini G. Ticlopidine-theophylline interaction. Clinical Pharmacology and Therapeutics 1987; 41: 358–362
- Danhoff M., Van Zuilen A., Boeijinga J. K., Breimer D. D. Studies of the different metabolic pathways of antipyrine in man: oral versus i.v. administration and the influence of urinary collection time. European Journal of Clinical Pharmacology 1982; 21: 433–441
- Danhoff M., Teunissen M. W. E. Antipyrine as a model drug to assess oxidative drug metabolizing activity in man. Pharmacy International January, 1984; 11–15
- David J. L., Monfort F., Herion F., Raskinet R. Compared effects of three dose levels of ticlopidine on platelet function in normal subjects. Thrombosis Research 1979; 14: 35–49
- Ebihara A., Aoki N., Yoshida N., Sano M., Matsubayashi K., Suzuchi T. Clinical Pharmacology of a new anti-thrombotic agent, ticlopidine. Japanese Journal of Clinical Pharmacology 1978; 9: 395–402
- Gent M., Blakely J. A., Easton J. D., Ellis D. J., Hachinski V. C., Harbison J. W., Panak E., Roberts R. S., Sicurella J., Turpie A. G. G. The Canadian-American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215–1220
- Hass W. K., Easton J. D., Adams H. P., Pryse-Phillips W., Molony B. A., Anderson S., Kamm B. A randomised trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. New England Journal of Medicine 1989; 321: 501–507
- Janzon L., Bergqvist D., Boberg J., Boberg M., Eriksson I., Lingarde F., Persson G. Prevention of myocardial infarction and stroke in patients with intermittent claudication: Effects of Ticlopidine. Journal of Internal Medicine 1990; 227: 301–308
- Johnson M., Heywood J. B. Possible mode of action of ticlopidine: a novel inhibitor of platelet aggregation. Abstr. no. 872; Seventh International Congress of Thrombosis and Haemostasis, London. Thrombosis and Haemostasis 1979; 42: 367–369
- Johnson M., Bastain W., Reeves P. Ticlopidine: a potent inhibitor of platelet aggregation in man. World Conference on Clinical Pharmacology and Therapeutics,London,August, 3–91980, Abstract no. 02299
- Knudsen J. B., Gormsen J. The effects of ticlopidine in normal volunteers and in patients with platelet hyperaggregability. in vitro. Thrombosis Research 1979; 16: 663–671
- Panak E., Maffrand J. P., Picard-Fraire C., Vallee E., Blanchard J., Roncucci R. Ticlopidine: a promise for the prevention and treatment of thrombosis, and its complications. Haemostasis 1983; 13(suppl. 1)1–54
- Picard-Fraire C. Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function. Agents and Actions 1984; 15(suppl.)68–75, In Ticlopidine: QUO VADIS?, edited by J. L. Gordon
- Anticonvulsant Drugs and Enzyme Induction. Proceedings of Study Group 9 of the Institute for Research into Mental and Multiple Handicaps. 1976, A. Richens, F. P. Woodford. Elsevier North-Holland, Amsterdam 1976
- Saltiel E., Ward A. Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987; 34: 222–262
- Thebault J. J., Blatrix C. E., Blanchard J. F., Panak E. A. Effects of ticlopidine, a new platelet inhibitor in man. Clinical Pharmacology and Therapeutics 1975; 18: 485–490